Natural Killer (NK) Cell Therapy Market Research Report 2022 – Comprehensive Information on 100+ Companies and 185+ Drugs in Pipeline –

the “Natural Killer (NK) Cell Therapy – Pipeline Insight, 2022” clinical trials have been added to from offer.

Publisher’s report, “Natural Killer (NK) Cell Therapy – Pipeline Insight, 2022”, provides comprehensive insights on 100+ companies and 185+ drugs in development in the Natural Killer Cell Therapy pipeline landscape (NK).

It covers pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It further highlights inactive pipeline products in this space.

The report “Natural Killer (NK) cell therapy – Pipeline Insight, 2022” provides comprehensive information on the current scenario and growth prospects in the indication. A detailed picture of the Natural Killer (NK) Cell Therapy pipeline landscape is provided, which includes an overview of the disease and Natural Killer (NK) Cell Therapy treatment guidelines.

The assessment portion of the report includes an in-depth Natural Killer (NK) Cell Therapy business assessment and clinical evaluation of the pipeline products under development. In the report, a detailed description of the drug is given including the mechanism of action of the drug, clinical studies, NDA approvals (if any) and product development activities including technology, cell therapy collaborations Natural Killer (NK), licenses, mergers. and acquisition, financing, designations and other product-related details.

Report Highlights

Companies and academics are scrambling to assess challenges and seek out opportunities that may influence Natural Killer (NK) cell therapy R&D. The therapies in development are focused on novel approaches to treat/enhance Natural Killer (NK) cell therapy.

Natural Killer (NK) Cell Therapy Emerging Drugs Chapters

This segment of the Natural Killer (NK) Cell Therapy report contains its detailed analysis of various drugs at different stages of clinical development including Phase II, I, Preclinical and Discovery. It also helps to understand details of clinical trials, expressive pharmacological action, agreements and collaborations, as well as the latest news and press releases.

Natural Killer (NK) Cell Therapy: Therapeutic Review

This segment of the report provides information on different Natural Killer (NK) Cell Therapy Drugs separated based on the following parameters which define the scope of the report such as:

Major Players in Natural Killer (NK) Cell Therapy

Approx. Over 100 key companies developing therapies for Natural Killer (NK) cell therapy. Among the companies whose Natural Killer (NK) cell therapy drug candidates are in the most advanced stage, i.e. Phase III, are the Nektar therapeutics.

Natural Killer (NK) Cell Therapy: Pipeline Development Activities

The report provides an overview of different therapeutic candidates in phase II, I, preclinical and discovery. It also analyzes the key Natural Killer (NK) Cell Therapy Therapeutic Drugs players involved in key drug development.

Pipeline development activities

The report covers the detailed information on collaborations, acquisitions and mergers, licenses as well as an in-depth therapeutic evaluation of new Natural Killer (NK) cell therapy drugs.

Key questions

  • How many companies are developing Natural Killer (NK) cell therapy drugs?

  • How many Natural Killer (NK) cell therapy drugs are developed by each company?

  • How many emerging drugs are in mid-stage and late-stage development for Natural Killer (NK) cell therapy treatment?

  • What are the major collaborations (industry-industry, industry-academia), mergers and acquisitions, licensing activities related to Natural Killer (NK) cell therapy?

  • What are the recent trends, types of drugs and new technologies developed to overcome the limitations of existing therapies?

  • What are the ongoing clinical studies for Natural Killer (NK) cell therapy and their status?

  • What are the key designations that have been granted to pipeline drugs?

Main topics covered:



Natural Killer (NK) Cell Therapy: Overview

  • causes

  • Action mechanism

  • Signs and symptoms

  • Diagnostic

  • Disease management

Pipeline therapeutics

Therapeutic assessment

  • Assessment by product type

  • Assessment by stage and type of product

  • Evaluation by route of administration

  • Assessment by stage and route of administration

  • Evaluation by type of molecule

  • Evaluation by stage and type of molecule

Late-stage products (Phase III)

  • Comparative analysis

  • NKTR-214: Therapeutic Nektar

  • Product Description

  • Research and development

  • Product development activities

Mid-term products (Phase II)

  • Comparative analysis

  • CellProtect: XNK Therapeutics

  • Product Description

  • Research and development

  • Product development activities

Early Stage Products (Phase I/II)

  • Comparative analysis

  • Anti-CD33 CAR-NK Cells: PersonGen BioTherapeutics

  • Product Description

  • Research and development

  • Product development activities

Inactive products

  • Comparative analysis

  • Natural Killer (NK) Cell Therapy – Key Companies

  • Natural Killer (NK) Cell Therapy – Key Products

  • Natural Killer (NK) Cell Therapy – Unmet Needs

  • Natural Killer (NK) Cell Therapy – Market Drivers and Barriers

  • Natural Killer (NK) Cell Therapy – Future Perspectives and Conclusion

  • Natural Killer (NK) Cell Therapy – Analyst Opinions

  • Natural Killer (NK) Cell Therapy – Key Companies


Companies cited

  • ImmunityBio

  • Cantargia

  • Cure Tech

  • Dynavax

  • Cellid

  • Abivax

  • asserted

  • Cellularity

  • Glycostem Therapeutics (IPD Therapeutics)


  • Céliade

  • Acepodes

  • Alllife Medical Science and Technology

  • Bright Path Biotherapeutic

  • Cytovia therapeutics

  • CytoImmune Therapeutics

  • Exacis Biotherapeutics

  • Novocellbio

  • Kuur Therapeutics (Former name: Cell Medica)

  • fate therapy

  • Feldan Therapeutic

  • iCell Gene Therapeutics

  • Innate Pharma

  • Therapeutic Nkarta

  • Surface oncology

  • Kiadis Pharma

  • Vycellix

  • INmune Organic

  • CiMass

  • glycostem

  • Five Prime Therapeutics

  • Multimmune GmbH

  • Atmosphere

  • Bellicum Pharmaceuticals

  • CARsgen therapeutics

  • Therapeutic Kuur

  • Céliade

  • Therapeutic Dragonfly

  • Gamida cell

  • NantKwest

  • Asclepius Technology Company

  • AffimedTherapeutics

  • Apceth Biopharma

  • Zelluna Immunotherapy

  • Organic catamaran

  • ONK therapy

  • Orgenesis

  • Navrogen


  • Therapeutic Nektar

  • Asserted therapy

  • HerbiCell

  • Bristol Myers Squibb

  • CellProtect Nordic Pharmaceuticals

  • CytoVac

  • Green Cross Society

  • NantKwest

  • PersonGen BioTherapeutics (Suzhou)

  • GT Biopharma (formerly Oxis International Inc.)

  • Therapeutic Nektar

  • Artiva Biotherapeutics

  • Senti Biosciences

  • onKo-innate

  • Asserted therapy

  • Agenus

  • Chongqing Sidemu Biotechnology

  • NKGen Biotech

  • Caribou Biosciences

  • Gamida cell

  • Wugen

  • Mussel

  • Therapeutics of the century

  • KSQ therapeutics

  • GT Biopharma

  • Coastal biosciences

  • Indapta Therapy

  • HebeCell

  • Sorrento Therapy

  • Organic Appia

  • Therapeutic Cellatoz

  • Sanofi

  • Glycotype

  • CiMaas

  • Coimmune

  • Editas Medicine

  • Helios

  • Chimeric therapy

  • Therapeutic Rubius

  • Eternal Therapy

  • MedXCell

  • Therapeutic MinK

  • Phio Pharmaceuticals

  • Biohaven Pharmaceuticals

  • Lava therapy

  • Allogeneic Therapeutic/Notch Therapeutic

  • Forward therapy

  • Miltenyi Biotec

For more information on this clinical trial report, visit